FindTrial
Sign In

Sevelamer HCl

DRUG5 trials

Sponsors

Ineos Healthcare Limited, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novartis Pharmaceuticals, Chugai Pharma Taiwan

Conditions

Cardiovascular EventsChronic Kidney DiseaseChronic Kidney FailureHemodialysisHyperphosphatemiaHyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement TherapyRenal OsteodystrophySecondary Hyperparathyroidism

Phase 2

Dose Ranging Study of Magnesium Iron Hydroxycarbonate in Haemodialysis Subjects With Hyperphosphataemia
CompletedNCT00436683
Ineos Healthcare LimitedChronic Kidney Failure
Start: 2007-02-28End: 2008-04-30Updated: 2009-08-10
Regulation of Bone Formation in Renal Osteodystrophy
CompletedNCT00560300
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Renal Osteodystrophy, Secondary Hyperparathyroidism
Start: 2000-11-30End: 2006-11-30Updated: 2010-01-14
Efficacy of SBR759 in Lowering Serum Phosphate Levels in Chronic Kidney Disease Patients on Hemodialysis
CompletedNCT00704483
Novartis PharmaceuticalsHyperphosphatemia Patients With Chronic Kidney Disease on 3x/Week Replacement Therapy
Start: 2008-07-31Updated: 2020-12-19
Optimal Titration Regimen for SBR759 in Lowering Serum Phosphate Levels in Asian Chronic Kidney Disease Patients on Hemodialysis
CompletedNCT00704678
Novartis PharmaceuticalsChronic Kidney Disease
Start: 2008-08-31Updated: 2016-09-23

Phase 4

Long Term Evaluation of Sevelamer HCl vs. Calcium-based Phosphate Binder in the Treatment of Hyperphosphatemia in Hemodialysis Patients
CompletedNCT01755078
Chugai Pharma TaiwanCardiovascular Events, Hemodialysis, Hyperphosphatemia
Start: 2007-06-30End: 2009-06-30Updated: 2014-08-05